Obefazimod is a small molecule commercialized by Abivax, with a leading Phase III program in Ulcerative Colitis. According to Globaldata, it is involved in 21 clinical trials, of which 14 were completed, 6 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Obefazimod’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Obefazimod is expected to reach an annual total of $268 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Obefazimod Overview
ABX-464 is under development for the treatment of ulcerative colitis, Chron's disease and other inflammatory indications. The drug candidate is first in class small molecule administered through the oral route as a capsule. The drug candidate acts by targeting Rev activity by blocking the cap-binding complex (CBC) on mRNA. It also acts by upregulating IL-22 and miR124. The drug candidate is based on Antiviral platform.
It was under development for the treatment of acute respiratory distress syndrome (ARDS) in COVID-19 patients, Crohn's disease, rheumatoid arthritis, multiple sclerosis, Parkinson's disease, psoriasis, HIV infection, non-alcoholic steatohepatitis (NASH) and pulmonary arterial hypertension.
Abivax Overview
Abivax is a biopharmaceutical company that primarily focuses on the discovery and development of novel treatments for chronic inflammatory diseases. The company offers product obefazimod, developed for the treatment of inflammatory diseases, starting with ulcerative colitis. Its pipeline products include obefazimod, ABX464 and ABX196. The company’s ABX196 treats hepatocellular carcinoma, obefazimod for Crohn’s disease and others. Abivax’s products are aimed at patients suffering from chronic inflammatory conditions of the gastrointestinal tract, such as ulcerative colitis and Crohn’s disease. The company also develops various technology platforms including an antiviral platform, immune enhancer platform and polyclonal antibody platform. It operates in France. Abivax is headquartered in Paris, France.
The operating loss of the company was EUR127.4 million in FY2023, compared to an operating loss of EUR70.5 million in FY2022. The net loss of the company was EUR147.7 million in FY2023, compared to a net loss of EUR69.9 million in FY2022.
For a complete picture of Obefazimod’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
